Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) just unveiled an announcement.
Imugene Limited announced a change in the director’s interest, specifically regarding Leslie Chong’s holdings. The change involved the acquisition of 170,405 direct ordinary fully paid shares and the disposal of an equivalent number of performance rights under the Employee Share Option Plan. This adjustment reflects the company’s ongoing efforts to align executive interests with shareholder value, potentially impacting stakeholder perceptions and reinforcing Imugene’s commitment to its strategic goals.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of novel therapies that harness the immune system to treat and eradicate cancer. The company’s primary products include immuno-oncology therapies, which are designed to activate the immune system against cancer cells, positioning Imugene as a key player in the cancer treatment market.
Average Trading Volume: 688,967
Technical Sentiment Signal: Sell
Current Market Cap: A$70.31M
Learn more about IMU stock on TipRanks’ Stock Analysis page.